Two inSPire2026 posters detail how health system specialty pharmacy teams support patients with ATTR-CM.
|Articles|September 1, 1996
The American Journal of Managed Care
- September 1996
- Volume 2
- Issue 8
Establishing the Basis for Successful Disease Management Contracting
Advertisement
Articles in this issue
about 30 years ago
Potential Cost-Effectiveness of Acute Stroke Treatmentabout 30 years ago
Potential for SSRIs as Monotherapy for Comorbid Psychiatric Disordersabout 30 years ago
Accreditation Standards in Managed Careabout 30 years ago
A Closer Look at CapitationAdvertisement
Related to this article
Patients with Sjögren disease diagnosed over a year after symptom onset had 2.3 times the odds of moderate or greater disease activity, a US survey found.
An estimated 44,052 sports eye injuries were treated in 2025 and 1262 pickleball eye injuries in 2024; 99% of lawnmower eye injuries were at home.
Teva's Weltruza, a once-monthly subcutaneous olanzapine injection, requires no loading doses, oral supplementation, or postinjection monitoring.
Population growth and aging, not rising age-standardized rates, drives the increase, with underlying causes varying widely by age and region.
The FDA approves atezolizumab with a fluoropyrimidine and oxaliplatin as adjuvant therapy for stage III dMMR colon cancer based on the ATOMIC trial.
Washington, DC, clinicians shared how order sets, pharmacist-led dosing, and better handoffs can close iron deficiency gaps in heart failure care.
Michael Mina, MD, PhD, explains Invivyd's accelerated approval path for VYD2311 and how it could change the timing of COVID-19 protection.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves IV, Subcutaneous Atezolizumab for dMMR Colon Cancer
2
5 Things to Know if Retatrutide Is Classified as a Biologic
3
FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia
4
Bumetanide Nasal Spray Targets Heart Failure Edema Before IV
5